WallStreetZenWallStreetZen

NASDAQ: XENE
Xenon Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for XENE

Based on 4 analysts offering 12 month price targets for Xenon Pharmaceuticals Inc

Min Forecast
$50.00+43.76%
Avg Forecast
$57.50+65.32%
Max Forecast
$67.00+92.64%

Should I buy or sell XENE stock?

Based on 4 analysts offering ratings for Xenon Pharmaceuticals Inc.

Strong Buy
Strong Buy
1 analysts 25%
Buy
3 analysts 75%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although XENE's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates XENE as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -9.02% per year. Learn More

Be the first to know when Wall Street analysts revise their XENE stock forecasts and price targets.

XENE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-02-24
lockedlocked$00.00+00.00%2025-02-11
lockedlocked$00.00+00.00%2024-11-13
lockedlocked$00.00+00.00%2024-10-10

1 of 1

Forecast return on equity

Is XENE forecast to generate an efficient return?

Company
-25.21%
Industry
154.79%
Market
88.2%
XENE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is XENE forecast to generate an efficient return on assets?

Company
-23.85%
Industry
32.71%
XENE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

XENE earnings per share forecast

What is XENE's earnings per share in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
-$4.17
Avg 2 year Forecast
-$4.54
Avg 3 year Forecast
-$4.50

XENE revenue forecast

What is XENE's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$7.5M
Avg 2 year Forecast
$29.6M
Avg 3 year Forecast
$78.6M

XENE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
XENE$34.78$57.50+65.32%Strong Buy
FOLD$8.52$16.86+97.85%Strong Buy
ACAD$17.03$24.17+41.91%Buy
RXRX$6.17$9.00+45.87%Buy
NAMS$22.56$44.40+96.81%Buy
View Top Biotech Stocks

Xenon Pharmaceuticals Stock Forecast FAQ

Is Xenon Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: XENE) stock is to Strong Buy XENE stock.

Out of 4 analysts, 1 (25%) are recommending XENE as a Strong Buy, 3 (75%) are recommending XENE as a Buy, 0 (0%) are recommending XENE as a Hold, 0 (0%) are recommending XENE as a Sell, and 0 (0%) are recommending XENE as a Strong Sell.

If you're new to stock investing, here's how to buy Xenon Pharmaceuticals stock.

What is XENE's earnings growth forecast for 2025-2027?

(NASDAQ: XENE) Xenon Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.81%.

Xenon Pharmaceuticals's earnings in 2025 is -$234,330,000.On average, 11 Wall Street analysts forecast XENE's earnings for 2025 to be -$319,428,459, with the lowest XENE earnings forecast at -$357,454,927, and the highest XENE earnings forecast at -$244,936,995. On average, 10 Wall Street analysts forecast XENE's earnings for 2026 to be -$347,420,165, with the lowest XENE earnings forecast at -$414,096,608, and the highest XENE earnings forecast at -$280,912,116.

In 2027, XENE is forecast to generate -$344,534,501 in earnings, with the lowest earnings forecast at -$440,121,163 and the highest earnings forecast at -$267,899,839.

What is XENE's revenue growth forecast for 2025-2027?

(NASDAQ: XENE) Xenon Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.7%.

Xenon Pharmaceuticals's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast XENE's revenue for 2025 to be $574,071,083, with the lowest XENE revenue forecast at $574,071,083, and the highest XENE revenue forecast at $574,071,083. On average, 4 Wall Street analysts forecast XENE's revenue for 2026 to be $2,268,728,918, with the lowest XENE revenue forecast at $1,148,142,165, and the highest XENE revenue forecast at $4,421,342,392.

In 2027, XENE is forecast to generate $6,018,101,972 in revenue, with the lowest revenue forecast at $3,185,711,794 and the highest revenue forecast at $12,246,849,760.

What is XENE's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: XENE) forecast ROA is -23.85%, which is lower than the forecast US Biotechnology industry average of 32.71%.

What is XENE's Price Target?

According to 4 Wall Street analysts that have issued a 1 year XENE price target, the average XENE price target is $57.50, with the highest XENE stock price forecast at $67.00 and the lowest XENE stock price forecast at $50.00.

On average, Wall Street analysts predict that Xenon Pharmaceuticals's share price could reach $57.50 by Feb 24, 2026. The average Xenon Pharmaceuticals stock price prediction forecasts a potential upside of 65.32% from the current XENE share price of $34.78.

What is XENE's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: XENE) Xenon Pharmaceuticals's current Earnings Per Share (EPS) is -$3.01. On average, analysts forecast that XENE's EPS will be -$4.17 for 2025, with the lowest EPS forecast at -$4.67, and the highest EPS forecast at -$3.20. On average, analysts forecast that XENE's EPS will be -$4.54 for 2026, with the lowest EPS forecast at -$5.41, and the highest EPS forecast at -$3.67. In 2027, XENE's EPS is forecast to hit -$4.50 (min: -$5.75, max: -$3.50).

What is XENE's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: XENE) forecast ROE is -25.21%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.